Soligenix, Inc. (SNGX) Fair Value 2026

SNGX · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.8 /10

32 fundamental signals · 1 models active

Value Trap Risk

LOW (39/100)

Quick Summary — As of 2026-08-28, Soligenix, Inc. (SNGX) trades at $0.38. QOC: 4.8/10. Value Trap Risk: 39/100 (LOW). 1/13 models active.

Key Facts

Ticker
SNGX
Price
$0.38
Quality Score
4.8/10
Value Trap Risk
39/100
Models Active
1/13
Last Updated
Strength: ML-RIV suggests +25.3% upside with 47% confidence
Risk: Below-average Quality Score of 4.8/10 signals weak fundamentals

What Fair Value Does Each Model Give SNGX?

1 Intrinsic Value Models vs. Current Price ($0.38)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · Medium Conviction
 $0.47 +25.3%

All Models Active

All 1 models are displayed above.

What Is Soligenix, Inc. (SNGX) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Soligenix, Inc. is potentially undervalued at its current price of $0.38. Based on our 13-model framework, Soligenix, Inc.'s intrinsic value is estimated at a median fair value of $0.47 — representing +25.3% implied upside — with 1 out of 1 active models confirming this thesis.

What Do the Models Say About SNGX?

1 of 13 models are currently active for SNGX. All 1 active models suggest the stock trades below fair value. See which stocks rank higher →

How Does SNGX Rank in Biotechnology?

Among 625 Biotechnology stocks, SNGX ranks #373 by Quality of Company score. CirclFi's QOC score of 4.8/10 evaluates 32 fundamental signals. A score of 4.8 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

Soligenix, Inc.'s positioning within the Biotechnology segment means that R&D burn rate plays an outsized role in fundamental analysis. The sector's unique characteristics — including platform technology validation — shape both the opportunity set and risk profile.

Is SNGX a Value Trap?

CirclFi's Value Trap algorithm assigns SNGX a score of 39/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for Soligenix, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, Soligenix, Inc. earns a quality score of 4.8/10. This mixed rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every SNGX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across SNGX's 1 active models, average confidence is 47%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Soligenix, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

TRVITrevi Therapeutics, Inc.QOC 4.8CNSYCerenome, Inc.QOC 4.8VKTXViking Therapeutics, Inc.QOC 4.8TTRXTurn Therapeutics Inc.QOC 4.8KPTIKaryopharm Therapeutics Inc.QOC 4.8QNCXQuince Therapeutics, Inc.QOC 4.8PDSBPDS Biotechnology CorporationQOC 4.1TNGXTango Therapeutics, Inc.QOC 6.8ABVXABIVAX Société AnonymeQOC 5.5EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: TRVI · CNSY · VKTX · TTRX · KPTI · QNCX · PDSB · TNGX · ABVX · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to SNGX?

7 companies across all industries closest to SNGX’s Quality of Company score of 4.8/10.

FEEDENvue Medical, Inc.QOC 4.8CNTMConnectM Technology Solutions, Inc.QOC 4.8TGLTreasure Global Inc.QOC 4.8TRIBTrinity Biotech plcQOC 4.8BEEPMobile Infrastructure CorporationQOC 4.8IVHIInvech Holdings, Inc.QOC 4.8NVDANVIDIA CorporationQOC 10.0

Read investment analysis: FEED · CNTM · TGL · TRIB · BEEP · IVHI · NVDA

Where Does SNGX Sit in CirclFi's Biotechnology Rankings?

SNGX is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Soligenix, Inc.’s Valuation?

What is Soligenix, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Soligenix, Inc. (SNGX). The Quality of Company score is 4.8/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is SNGX overvalued or undervalued right now?

At $0.38, 1 of 1 active models suggest SNGX may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Soligenix, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 4.8 mean for SNGX?

Soligenix, Inc.'s QOC of 4.8/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on SNGX?

CirclFi analyzes SNGX with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is SNGX a value trap in 2026?

Soligenix, Inc.'s Value Trap score is 39/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Soligenix, Inc. (SNGX) a Quality of Company score of 4.8/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/SNGX/ · Methodology
Primary sources for this SNGX valuation
  • Financial statements: Soligenix, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0000812796) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for SNGX as of ; valuations recomputed .